Howard C. Dittrich
Founder at Advanced Endovascular Therapeutics, Inc.
Profile
Howard C.
Dittrich founded NovaCardia, Inc. in 2001, where he worked as Chief Medical Officer & SVP-Regulatory Affairs from 2001 to 2007, Farapulse, Inc. in 2014, where he worked as Chairman from 2014 to 2016, Sequel Pharmaceuticals, Inc. in 2007, where he worked as Chief Medical Officer from 2007 to 2011, Laguna Pharmaceuticals, Inc. in 2006, where he worked as Chief Medical Officer from 2011 to 2015, and Advanced Endovascular Therapeutics, Inc. in 2015, where he is working as President & Director from 2015.
Dr. Dittrich also founded Hawkeye Therapeutics, Inc., where he worked as Chief Medical Officer.
Dr. Dittrich also currently works at François M.
Abboud Cardiovascular Research Center, as Chairman from 2012 and Cirius Therapeutics, Inc., as Chief Medical Officer.
Dr. Dittrich also formerly worked at Mast Therapeutics, Inc., as Independent Director from 2014 to 2017, Savara, Inc., as Director, Alliance Pharmaceutical Corp., as Chief Medical Officer & Vice President from 2001 to 2002, Molecular Biosystems, Inc., as Vice President-Research & Regulatory Affairs from 1996 to 2002, Sorbent Therapeutics, Inc., as Chief Medical Officer from 2012 to 2014, the University of California, Berkeley, as Member, and the University of California San Diego, as Clinical Professor in 2011.
Dr. Dittrich received his undergraduate degree from the University of Iowa and doctorate degree from the University of Iowa Carver College of Medicine.
Howard C. Dittrich active positions
| Companies | Position | Start |
|---|---|---|
Advanced Endovascular Therapeutics, Inc.
 Advanced Endovascular Therapeutics, Inc. Medical SpecialtiesHealth Technology Advanced Endovascular Therapeutics, Inc. develops therapeutic apparatus. The private company is based in Dover. The American company was founded by Howard C. Dittrich. | Founder | 2015-07-31 |
| François M. Abboud Cardiovascular Research Center | Chairman | 2011-12-31 |
Cirius Therapeutics, Inc.
 Cirius Therapeutics, Inc. BiotechnologyHealth Technology Cirius Therapeutics, Inc. operates as a biotechnology company. It offers metabolic treatment for nonalcoholic steatohepatitis. The company was founded by Jerry R. Colca and Brian Finck and was founded in March 2017, and is headquartered in San Diego, CA. | Chief Tech/Sci/R&D Officer | - |
Former positions of Howard C. Dittrich
| Companies | Position | End |
|---|---|---|
| SAVARA INC. | Director/Board Member | 2017-04-26 |
Mast Therapeutics, Inc.
 Mast Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Mast Therapeutics, Inc. is a biopharmaceutical company, which engages in developing novel therapies for serious or life-threatening diseases with significant unmet needs. It leveraging Molecular Adhesion and Sealant Technology, platform, derived from over two decades of clinical, nonclinical, and manufacturing experience with purified and non-purified poloxamers to develop vepoloxamer, which also known as MST-188. The company was founded by Warren C. Lau in December 1995 and is headquartered in San Diego, CA. | Director/Board Member | 2017-03-31 |
Farapulse, Inc.
 Farapulse, Inc. Medical SpecialtiesHealth Technology Farapulse, Inc. engages in the development of medical devices. Its products are: Endo Farawave, a percutaneous catheter designed to create transmural and contiguous lesions on the endocardium of the left atrium to isolate the pulmonary veins and EPI Faraone, s designed to create a box lesion around all pulmonary veins from an epicardial placement of the catheter for the treatment of atrial fibrillation. The company was founded by Steven Mickelsen in 2014 and is headquartered in Iowa City, IA. | Founder | 2016-01-31 |
Laguna Pharmaceuticals, Inc.
 Laguna Pharmaceuticals, Inc. BiotechnologyHealth Technology Laguna Pharmaceuticals, Inc. develops and manufactures biopharmaceutical products. Its lead product, Vanoxerine is a therapeutic candidate being developed for treatment of atrial fibrillation and atrial flutter. The firm’s product is a potential pharmaceutical option to rapidly terminate atrial fibrillation in both hospital and home settings. The company was founded in 2006 by Arthur M. Brown and Howard C. Dittrich and is headquartered in Cleveland, OH. | Founder | 2015-10-31 |
Sorbent Therapeutics, Inc.
 Sorbent Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Sorbent Therapeutics, Inc. develops therapies for cardiovascular and renal diseases. It focuses on the development of non-absorbed polymeric drugs to satisfy unmet clinical needs in large cardiovascular and renal markets such as heart failure, chronic kidney disease and hypertension. The company was founded by William R. Rajski, Dean Abrassart, Donald W. Joseph and Lee W. Henderson on January 25, 2005 and is headquartered in Sunnyvale, CA. | Chief Tech/Sci/R&D Officer | 2014-06-30 |
Training of Howard C. Dittrich
| University of Iowa | Undergraduate Degree |
| University of Iowa Carver College of Medicine | Doctorate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Listed companies | 1 |
|---|---|
| SAVARA INC. | Health Technology |
| Private companies | 12 |
|---|---|
NovaCardia, Inc.
 NovaCardia, Inc. Pharmaceuticals: MajorHealth Technology NovaCardia, Inc. develops drugs to treat cardiovascular diseases. The company provides treatment for the patients by developing and commercializing clinical stage drug diseases. It also develops small molecule drugs. the company was founded in November, 2001 by Eckard Weber & Howard C. Dittrich and is headquartered in San Diego, CA. | Health Technology |
Alliance Pharmaceutical Corp.
 Alliance Pharmaceutical Corp. BiotechnologyHealth Technology Alliance Pharmaceutical Corp. is a research & development company, which focused on transformed innovative scientific discovered into novel therapeutic and diagnostic agents. It currently focused on developed its lead product, Oxygent, an intravascular oxygen carrier designed to augment oxygen deliveryed in surgical patients. The company was founded by Duane J. Roth in 1983 and is headquartered in San Diego, CA. | Health Technology |
Molecular Biosystems, Inc.
 Molecular Biosystems, Inc. Medical SpecialtiesHealth Technology Molecular Biosystems, Inc. develops, makes and sells ultrasound contrast imaging agents. The company was founded by Kenneth J. Widder, Richard H. Tullis, Drew E. Senyei and Lyle J. Arnold and is headquartered in San Diego, CA. | Health Technology |
Sequel Pharmaceuticals, Inc.
 Sequel Pharmaceuticals, Inc. Drugstore ChainsRetail Trade Sequel Pharmaceuticals, Inc. engaged in the development of cardiovascular drug. The company was founded in 2007 and was headquartered in San Diego, CA. | Retail Trade |
Sorbent Therapeutics, Inc.
Sorbent Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Sorbent Therapeutics, Inc. develops therapies for cardiovascular and renal diseases. It focuses on the development of non-absorbed polymeric drugs to satisfy unmet clinical needs in large cardiovascular and renal markets such as heart failure, chronic kidney disease and hypertension. The company was founded by William R. Rajski, Dean Abrassart, Donald W. Joseph and Lee W. Henderson on January 25, 2005 and is headquartered in Sunnyvale, CA. | Health Technology |
Mast Therapeutics, Inc.
Mast Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Mast Therapeutics, Inc. is a biopharmaceutical company, which engages in developing novel therapies for serious or life-threatening diseases with significant unmet needs. It leveraging Molecular Adhesion and Sealant Technology, platform, derived from over two decades of clinical, nonclinical, and manufacturing experience with purified and non-purified poloxamers to develop vepoloxamer, which also known as MST-188. The company was founded by Warren C. Lau in December 1995 and is headquartered in San Diego, CA. | Health Technology |
Laguna Pharmaceuticals, Inc.
Laguna Pharmaceuticals, Inc. BiotechnologyHealth Technology Laguna Pharmaceuticals, Inc. develops and manufactures biopharmaceutical products. Its lead product, Vanoxerine is a therapeutic candidate being developed for treatment of atrial fibrillation and atrial flutter. The firm’s product is a potential pharmaceutical option to rapidly terminate atrial fibrillation in both hospital and home settings. The company was founded in 2006 by Arthur M. Brown and Howard C. Dittrich and is headquartered in Cleveland, OH. | Health Technology |
Farapulse, Inc.
Farapulse, Inc. Medical SpecialtiesHealth Technology Farapulse, Inc. engages in the development of medical devices. Its products are: Endo Farawave, a percutaneous catheter designed to create transmural and contiguous lesions on the endocardium of the left atrium to isolate the pulmonary veins and EPI Faraone, s designed to create a box lesion around all pulmonary veins from an epicardial placement of the catheter for the treatment of atrial fibrillation. The company was founded by Steven Mickelsen in 2014 and is headquartered in Iowa City, IA. | Health Technology |
Hawkeye Therapeutics, Inc.
 Hawkeye Therapeutics, Inc. BiotechnologyHealth Technology Hawkeye Therapeutics, Inc. licenses and develops assets from pharmaceutical companies. The company is headquartered in San Diego, CA. | Health Technology |
Advanced Endovascular Therapeutics, Inc.
Advanced Endovascular Therapeutics, Inc. Medical SpecialtiesHealth Technology Advanced Endovascular Therapeutics, Inc. develops therapeutic apparatus. The private company is based in Dover. The American company was founded by Howard C. Dittrich. | Health Technology |
| François M. Abboud Cardiovascular Research Center | |
Cirius Therapeutics, Inc.
Cirius Therapeutics, Inc. BiotechnologyHealth Technology Cirius Therapeutics, Inc. operates as a biotechnology company. It offers metabolic treatment for nonalcoholic steatohepatitis. The company was founded by Jerry R. Colca and Brian Finck and was founded in March 2017, and is headquartered in San Diego, CA. | Health Technology |
- Stock Market
- Insiders
- Howard C. Dittrich
